| Original language | English (US) |
|---|---|
| Pages (from-to) | 1680-1682 |
| Number of pages | 3 |
| Journal | JAMA internal medicine |
| Volume | 177 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2017 |
ASJC Scopus subject areas
- Internal Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Trends and characteristics of US Medicare spending on repository corticotropin. / Hartung, Daniel M.; Johnston, Kirbee; Van Leuven, Shelby; Deodhar, Atul; Cohen, David M.; Bourdette, Dennis N.
In: JAMA internal medicine, Vol. 177, No. 11, 11.2017, p. 1680-1682.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Trends and characteristics of US Medicare spending on repository corticotropin
AU - Hartung, Daniel M.
AU - Johnston, Kirbee
AU - Van Leuven, Shelby
AU - Deodhar, Atul
AU - Cohen, David M.
AU - Bourdette, Dennis N.
N1 - Funding Information: Published Online: September 11, 2017. doi:10.1001/jamainternmed.2017.3631 Author Contributions: Dr Hartung had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Hartung, Deodhar, Cohen, Bourdette. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Hartung, Johnson, Van Leuven. Critical revision of the manuscript for important intellectual content: Hartung, Deodhar, Cohen, Bourdette. Statistical analysis: Hartung, Johnston, Van Leuven. Obtained funding: Hartung, Bourdette. Administrative, technical, or material support: Johnston, Van Leuven. Study supervision: Hartung, Bourdette. Conflict of Interest Disclosures: Dr Deodhar reports receiving research grants from Amgen, Abbvie, Janssen, GSK, Eli Lilly, Novartis, Pfizer, Sun Pharma, and UCB. He also services on advisory boards for Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, and UCB. No other disclosures are reported. Funding/Support: This study was supported by the National Multiple Sclerosis Society. Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Additional Contributions: We thank Luke Middleton, BS, College of Pharmacy, Oregon State University/Oregon Health & Science University, Portland, for assistance with data management. 1. Ornstein C. the obscure drug with a growing Medicare tab. ProPublica. August 4, 2014. https://www.propublica.org/article/the-obscure-drug-with -a-growing-medicare-tab. Accessed July 17, 2017. 2. Ornstein C. Top Acthar prescribers in Medicare have ties to its maker. ProPublica. August 4, 2014. https://www.propublica.org/article/top-acthar -prescribers-in-medicare-have-ties-to-its-maker. Accessed July 17, 2017.
PY - 2017/11
Y1 - 2017/11
UR - http://www.scopus.com/inward/record.url?scp=85033578230&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85033578230&partnerID=8YFLogxK
U2 - 10.1001/jamainternmed.2017.3631
DO - 10.1001/jamainternmed.2017.3631
M3 - Article
C2 - 28892525
AN - SCOPUS:85033578230
VL - 177
SP - 1680
EP - 1682
JO - JAMA Internal Medicine
JF - JAMA Internal Medicine
SN - 2168-6106
IS - 11
ER -